Condition: Depression and Quality of Life · Treatment Resistant Depression (TRD) · Anhedonia · Sponsor: Riccardo Guglielmo
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.
This description comes directly from the study's public registry record.
Riccardo Guglielmo, MD · +390105552202 · riccardo.guglielmo@unige.it
Elisa Cavanna, MD · +390105552202 · elisa.cavanna01@gmail.com
Always discuss trial participation with your own doctor first.
| Ospedale Policlinico San Martino | Genova, Ge, Italy | Recruiting |
| Csm Dds 8 | Genova, Ge, Italy | Recruiting |
| Università di Chieti | Chieti, Italy | Recruiting |
| ASST Fatebenefratelli Sacco | Milan, Italy | Recruiting |
| ASST Pavia | Pavia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07146503